Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Medication treatment (MT) is one of the few evidence-based strategies proposed to combat the current opioid epidemic. We examined national trends and correlates of offering MT in substance use treatment facilities in the United States. According to data from national surveys, the proportion of these facilities that offered any MT increased from 20.0 percent in 2007 to 36.1 percent in 2016-mainly the result of increases in offering buprenorphine and extended-release naltrexone. Only 6.1 percent of facilities offered all three MT medications in 2016. Facilities in states with higher opioid overdose death rates, facilities that accepted health insurance overall (and, more specifically, those that accepted Medicaid in states that opted to expand eligibility for Medicaid), and facilities in states with more comprehensive coverage of MT under their Medicaid plans had higher odds of offering MT. The findings highlight the persistent unmet need for MT nationally and the role of expansion of health insurance in the dissemination of these treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Vivolo-Kantor, A. M., Seth, P., Gladden, R. M., Mattson, C. L., Baldwin, G. T., Kite-Powell, A., & Coletta, M. A. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6709e1 · Cited by 428
Tanum, L., Solli, K. K., Latif, Z.-E.-H., Benth, J. Š., Opheim, A., Sharma-Haase, K., Krajci, P., & Kunøe, N. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3206 · Cited by 253
Saloner, B., Bandara, S., Bachhuber, M., & Barry, C. L. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201600182 · Cited by 85
Self-citationFeder, K. A., Mojtabai, R., Krawczyk, N., Young, A. S., Kealhofer, M., Tormohlen, K. N., & Crum, R. M. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.07.015 · Cited by 51
Self-citationTrends and key correlates of prescription opioid injection misuse in the United States
Jones, C. M. (2018) · Addictive Behaviors · doi:10.1016/j.addbeh.2017.10.018 · Cited by 37
Cited by
Comparative effectiveness of different treatment pathways for opioid use disorder.
Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.20622 · Cited by 995
Krawczyk, N., Mojtabai, R., Stuart, E. A., Fingerhood, M., Agus, D., Lyons, B. C., Weiner, J. P., & Saloner, B. (2020) · Addiction · doi:10.1111/add.14991 · Cited by 177
Self-citationThe Next Stage of Buprenorphine Care for Opioid Use Disorder
Martin, S. A., Chiodo, L. M., Bosse, J. D., & Wilson, A. (2018) · Annals of Internal Medicine · doi:10.7326/m18-1652 · Cited by 130
Park, T. W., Larochelle, M. R., Saitz, R., Wang, N., Bernson, D., & Walley, A. Y. (2020) · Addiction · doi:10.1111/add.14886 · Cited by 78
“In particular, more people are receiving buprenorphine(1,2), the most widely prescribed medication for opioid use disorder in substance use treatment facilities(3).”
BackgroundBurke, L. G., Zhou, X., Boyle, K. L., Orav, E. J., Bernson, D., Hood, M., Land, T., Bharel, M., & Frakt, A. B. (2020) · Addiction · doi:10.1111/add.14867 · Cited by 35
Metadata
- Authors
- Mojtabai, R., Mauro, C., Wall, M. M., Barry, C. L., & Olfson, M.
- Venue
- Health Affairs
- Publisher
- Health Affairs Publishing, LLC
- Published
- 2019-01
- Volume
- 38
- Issue
- 1
- Pages
- 14-23
- ISSN
- 0278-2715 (ISSN-L)
- 1544-5208
- OpenAlex
- W2907582570
- Cited by
- 157
- References
- 7
- FWCI
- 23.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities. https://app.cochat.ai/papers/10.1377/hlthaff.2018.05162
- The paper
- Mojtabai, R., Mauro, C., Wall, M. M., Barry, C. L., & Olfson, M. (2019). Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities. Health Affairs. https://doi.org/10.1377/hlthaff.2018.05162
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.